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ABSTRACT
Introduction: Acne is a common disease caused 
by multiple factors affecting the pilosebaceous 
follicles. As a result of the multifactorial nature 
of this disease, current treatment guidelines 
recommend using drugs from multiple classes. 
Adherence is a challenge when multiple drugs 
are needed in a treatment regimen. Newer 
combination products may help physicians 
combat this issue. The purpose of this paper was 
to examine prescribing patterns in the treatment 
of acne focusing on combination-product use.
Methods: The National Ambulatory Medical Care 
Survey database was queried for visits for acne. 
Visits were analyzed for patient demographics 
and treatment regimens. Prescription for 
common treatments and combination products 
were analyzed to determine changes in 
prescribing over time.
Results: The most common treatment for 
acne was topical retinoids. Two combination 
products were within the top 10 acne 
treatments. The use of combination products is 
increasing in primary care specialties (1.26% per 
year; P=0.002) as well as among dermatologists 
(0.66% per year; P<0.001). Primary care 
physicians (12.6%) prescribed combination 
products at a higher percentage of visits than 
did dermatologists (11.5%). 
Conclusion: The use of combination acne 
products is increasing. The use of combination 
products is expected to increase as a means of 
reducing treatment complexity and increasing 
adherence to treatment. 
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Acne vulgaris is an inflammatory condition 
occurring in more than 85% of adolescents 
with over 40% having persistent acne into their 
twenties and some continuing into adulthood 
[1,2]. Acne impairs quality of life and is 
associated with increased rates of depression, 
anxiety, and other psychological disorders 
[3-6]. Treatment is challenging in part because 
the pathophysiology of acne is complex. 
The disease is caused by multiple factors 
affecting the pilosebaceous follicles including: 
(1) alterations in keratinization; (2) follicle 
colonization with Propionibacterium acnes, 
which induces inflammation through toll-like 
receptors on inflammatory cells; (3) release of 
inflammatory mediators into the skin including 
matrix metalloproteinases; and (4) increases in 
sebum production with oxidized lipids further 
stimulating the production of inflammatory 
mediators [7]. Consensus guidelines recommend 
the use of drugs from multiple drug classes 
to effectively combat the different causative 
factors of the disease [7,8]. Treatment includes 
topical retinoids to address comedones, 
antibiotics to decrease P. acnes counts and reduce 
inflammation, and benzoyl peroxide to help 
prevent development of resistant bacteria [9,10]. 
Adherence to topical medications is poor 
compared to oral medications, and acne 
medication adherence may be particularly 
poor in adolescent patients [11-13]. Patients 
may perceive topical acne medications as time 
consuming, messy, or inconvenient. Patients 
are challenged by incorporation of medication 
application into their daily routine, and may 
become discouraged when their acne does not 
improve quickly. Furthermore, out-of-pocket 
costs for topical medications may be high, 
and patients may be unwilling to pay for a 
medication that they recognize as ineffective [14]. 
Treatment failure may necessitate progression to 
more costly and potentially toxic therapies, such as 
oral antibiotics, hormonal therapy, or isotretinoin [8]. 
The need to utilize multiple products to address the 
different components of the pathogenesis of acne 
adds to the burden of treatment and the challenge 
of adhering to the treatment regimen.
Simplifying the treatment regimen, 
which can be accomplished with the use of 
combination products, improves adherence 
resulting in better outcomes for patients [15,16]. 
The purpose of this study was to assess the 
common treatments employed by prescribers, 
including dermatologists and primary care 
physicians. The authors assessed the number of 
individuals undergoing treatment for acne by 
each group and determined the most commonly 
used treatment regimens. The authors also 
focused on the use of combination products by 
both groups to determine whether the use of 
these products is changing over time. 
The National Center for Health Statistics (NCHS) 
conducts the National Ambulatory Medical 
Care Survey (NAMCS) to provide reliable 
information regarding the provision and use of 
medical care services in the United States. Data 
collection includes surveys completed by non-
federally employed outpatient health centers 
directly involved in patient care. Participating 
health centers are randomly assigned to a 
1-week collection period in which patient visits 
are systematically randomly sampled. Sampled 
visits are logged by a physician provider and 
include patients’ demographics, symptoms, 
physician’s diagnosis, procedures performed, 
and medications ordered. After the data are 
collected, sampling weights are applied to the 
data in order to project national estimates of 
outpatient healthcare utilization [17]. 
MATERIALS AND METHODS
INTRODUCTION
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In the present study, to assess the acne 
treatment practices of physicians in the 
United States, the NAMCS database was 
queried to identify all patient encounters from 
1989-2009 in which a sole diagnosis of “acne” 
was recorded; visits with multiple diagnoses 
were excluded in order to assure that identified 
medications were prescribed for the treatment 
of acne. The data were also restricted from 
2007-2009 to determine recent trends. The 
NAMCS database included both prescription 
and over-the-counter treatments discussed, 
dispensed, administered, and/or prescribed 
during the patient encounter. The authors 
compared prescribing patterns between 
dermatologists and primary care specialties, 
including family medicine, pediatrics, and 
internal medicine. The demographics of the 
patients seen by the different specialties 
were determined. The authors compiled the 
top 10 most prescribed acne medications; 
similar products were added together if there 
were more than one listing for the same 
generic chemical. 
Regression analyses were performed to assess 
prescribing patterns over time, from the years 
1989-2009. All data analysis was performed using 
SAS software (SAS Institute, Cary, NC, USA) and 
linear regression models were generated using 
SAS PROC SURVEYREG (SAS Institute).
There were an estimated 139 million patient visits 
for acne with 81.9 million patient visits with a sole 
diagnosis of acne from 1989-2009. Acne visits that 
had a sole diagnosis of acne were more common 
among dermatologists (66.7%) than among 
primary care physicians (35.3%). Dermatologists 
(84.8%) saw the majority of these patients; family 
physicians (7.2%), pediatricians (4.8%), and 
internal medicine physicians (2.9%) saw the other 
15% of patients. Visits for acne were more common 
among female patients among all specialties 
included in this study (Table 1). The most 
common age for treatment among dermatologists, 
family physicians, and pediatricians was between 
10-19 years, and the most common age for 
treatment for the internal medicine physicians was 
between 20-29 years (Table 1). 
The most commonly used acne medications 
in dermatology were tretinoin, isotretinoin, 
minocycline, adapalene, and tetracycline (Table 2). 
The products prescribed by the primary care 
specialists were different; however, tretinoin 
remained the number one treatment prescribed 
by both groups. Notably, dermatologists prescribed 
adapalene in 11% of patient visits and it was the 
fourth most commonly prescribed acne treatment, 
but it was not among the top 10 medications 
prescribed by primary care physicians. The top 
five prescribed acne treatments used by primary 
care specialties included the combination product 
erythromycin 3% and benzoyl peroxide 5%, 
whereas the top eight treatments used by 
dermatologists do not include any combination 
products. Both groups have two combination 
products, erythromycin 3% with benzoyl 
peroxide 5% and clindamycin 1% with benzoyl 
peroxide 5% within the top 10 drugs prescribed 
for acne treatment. 
In over 9.6 million patient encounters, a 
combination medication was prescribed from 
1989-2009. Primary care physicians (12.6%) 
prescribed combination products at a higher 
percentage of visits than did dermatologists 
(11.5%; Table 3). The frequency of prescribing 
a combination product increased over time for 
both dermatologists (P≤0.001) and primary care 
physicians (P=0.002). The upward trend in the 
use of combination products from 1989-2009 is 
higher among primary care physicians at 1.26% 
per year compared to 0.66% per year among 
dermatologists (Fig. 1). 
RESULTS
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From 2007-2009, primary care physicians 
(33.8%) prescribed combination products at a 
higher percentage of visits than did dermatologists 
(22.0%). For primary care physicians (P=0.38), 
there was a downward trend in the use of 
combination products of 11.4% per year and for 
dermatologists (P=0.66) there was an upward trend 
of 1.5% per year. The top five products used by 
dermatologists from 2007-2009 were isotretinoin, 
tretinoin, adapalene, clindamycin and benzoyl 
peroxide, and doxycycline. Similarly, the top five 
products used by primary care physicians were 
tetracycline, tretinoin, doxycycline, clindamycin 
and benzoyl peroxide, and erythromycin and 
benzoyl peroxide (Table 2). 
During the study time-period, dermatologists 
managed most of the patients with a sole 
diagnosis of acne. The treatment selections by 
dermatologists and primary care physicians 
were not drastically different. This study found 
the use of topical combination products to be 
increasing for both dermatologists and primary 
care physicians. Both groups are employing this 
form of treatment in approximately 11% of their 
acne patients. The rate of increase per year was 
greatest among the primary care providers but 
both groups show a steady increase in use over 
the study period. 
Table 1. Demographic information as NAMCS percentages in patient visits with acne as sole diagnosis from 1989 to 2009 
by gender, race, and age.
  Dermatology Family medicine Pediatrics Internal medicine
Gender
Female 62.64 54.18 55.57 62.13
Male 37.36 45.82 44.43 37.87
Race
White 85.4 83.49 71.06 91.85
Black 5.99 4.66 18.03 3.87
Asian 4.23 6.16 7.79 4.28
Other 4.38 5.69 3.12 0
Age (years)
0-9 0.75 1.53 16.39 0
10-19 50.2 67.77 81.5 34.10
20-29 25.46 17.38 0 37.96
30-39 14.20 8.97 0 19.79
40-49 6.65 2.04 0 4.39
50-59 1.62 2.30 0 2.31
60-69 0.54 0 2.12 1.45
70-79 0.40 0 0 0
80-89 0.16 0 0 0
90+ 0.01 0 0 0
NAMCS=The National Ambulatory Medical Care Survey.
DISCUSSION
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The top treatment by each group was 
topical tretinoin therapy. Topical retinoids were 
considered first-line therapy in acne treatment 
during the study period and some still consider 
topical retinoids to be the best first-line therapy 
for mild to moderate acne [16]. However, a 
recent review article by Webster found that in 
nine studies comparing topical combination 
therapy to retinoid monotherapy, topical 
combination therapy was more effective at 
reducing the acne lesion counts in eight of the 
nine studies [10]. Combination products with 
benzoyl peroxide also decrease the incidence 
of antibiotic resistance. In a study by Cunliffe 
et al. [18] 40 patients received combination 
treatment and 39 patients received topical 
antibiotic monotherapy. At the end of 
16 weeks of treatment, the P. acnes count and 
the clindamycin-resistant P. acnes count were 
significantly reduced in the combination 
treatment group when compared to topical 
clindamycin monotherapy [18]. Combination 
products reduce the necessity of prescribing 
multiple topical medications and simplify 
the treatment regimen. The advantages of 






















Fig. 1. Trends in the use of topical combination medications for the treatment of acne, 1989-2009.
Table 3. Use of combination products by dermatologists and primary care physicians, 1989-2009.
Product name
Year first introduced to  
the US market
Total dermatology visits, % 
(total number prescribed)
Total primary care visits, % 
(total number prescribed)
Erythromycin 3% and benzoyl 
peroxide 5% 26/10/84 6.3 (4,386,337) 7.9 (962,511)
Clindamycin 1% and benzoyl 
peroxide 5% 4.7 (3,265,092) 4.6 (567,937)21/12/00
Clindamycin phosphate 1.2% 
and tretinoin 0.025% 7/11/06 0.4 (314,320) 0
Adapalene 0.1% and benzoyl 
peroxide 2.5% 8/12/08 0.2 (138,581) 0.4 (45,647)
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the greater flexibility of using separate agents 
and the higher cost of combination versus 
monotherapy or multiple product regimens. 
There are several limitations of this study 
using the NAMCS database. The data were for 
visits with the sole diagnosis of acne. Primary 
care physicians and dermatologists often bill 
for multiple problems during a visit. Thus, the 
data under represents the true number of acne 
cases treated by both groups. The data were 
restricted in this way to increase the likelihood 
that the medications prescribed at the visit 
were for acne treatment. Another limitation of 
the data is that the severity of the acne was not 
established, so treatment differences by severity 
could not be ascertained. 
The final limitation in this study is that in 
recent years, many insurance companies have 
refused to cover the cost of topical combination 
medications. Combination products can be 
more expensive than the active ingredients 
prescribed separately; while the combination 
products have the advantage of reducing 
treatment complexity and improving treatment 
outcomes, the higher cost may have a significant 
impact on prescribing patterns of these products 
in the future. 
In conclusion, despite these limitations, the 
graphical presentation of the data from 1989-2009 
shows a clear picture of combination product 
use for acne over time. The use of combination 
products for acne is increasing among providers. 
The increased utilization of combination products 
may be secondary to improved availability 
over time and increased marketing of these 
products to patients and prescribers. Current 
acne treatment guidelines state that several drug 
classes should be used in the treatment of acne 
vulgaris [7,8]. Although the increased utilization 
of combination products may be due, in part, 
to greater availability and marketing of these 
products in recent years, the authors anticipate 
that this trend will continue because of the 
growing awareness of the need to use both topical 
retinoids and antimicrobial products and of the 
problem of poor adherence to complex acne 
treatment regimens. Combination product use 
improves efficacy and compliance compared to 
separate agents [11,15,19]. Combination products 
allow physicians to adhere to current acne 
treatment guidelines while prescribing a product 
that reduces application time and simplifies the 
treatment regimen when compared to prescribing 
two topical medications. 
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